Top Markets
Coin of the day
Regnum Corp. Regnum Corp.

Regnum Corp.

RGMP
Rank in Stocks #42305
Regnum Corp. is dedicated to advancing and marketing therapeutic agents... Regnum Corp. is dedicated to advancing and marketing therapeutic agents designed to combat both rare and infectious diseases. Its flagship product is Leronlimab (PRO 140), a monoclonal antibody functioning as a C-C chemokine receptor type 5 (CCR5) antagonist. This drug is specifically formulated to inhibit the human immunodeficiency virus (HIV) from gaining entry into human cells. Headquartered in New York, New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.30K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regnum Corp. (RGMP)

Category

Revenue for Regnum Corp. (RGMP)
Revenue in Aug 2026 TTM: 0
According to Regnum Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Regnum Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
- -
CH
$10.11B -
BE
- -
KR